Medindia

X

X-linked MeCP2 is a New Target for Treating Parkinson's Disease

by Rukmani Krishna on  August 13, 2013 at 11:56 PM General Health News   - G J E 4
In the regulation of neuronal development, proliferation and maturation, and synaptic regeneration and apoptosis, X-linked methyl-CpG binding protein 2 plays important role. Overexpression of X-linked methyl-CpG binding protein 2 in SH-SY5Y cells can reduce cell apoptosis induced by 6-hydroxydopamine and increased tyrosine hydroxylase expression. But the specific role of X-linked methyl-CpG binding protein 2 in the pathogenesis of Parkinson's disease remains unknown.
 X-linked MeCP2 is a New Target for Treating Parkinson's Disease
X-linked MeCP2 is a New Target for Treating Parkinson's Disease
Advertisement

Prof. Xianhou Yuan and team from Zhongnan Hospital of Wuhan University used 6-hydroxydopamine-induced human neuroblastoma cell (SH-SY5Y cells) injury as a cell model of Parkinson's disease. The researchers found that overexpression of X-linked methyl-CpG binding protein 2 was able to ameliorate the effects of 6-hydroxydopamine, it reduced 6-hydroxydopamine-induced apoptosis, and increased the levels of tyrosine hydroxylase in SH-SY5Y cells. These findings, published in the Neural Regeneration Research (Vol. 8, No. 21, 2013), suggesting that X-linked methyl-CpG binding protein 2 may be a potential therapeutic target for the treatment of Parkinson's disease.

Advertisement
Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All

More News on: